Evommune (EVMN) Net Cash Flow (2024 - 2026)

Evommune (EVMN) has 3 years of Net Cash Flow data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 140.27% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $29.0 million, up 327.23% from the prior year.
• Net Cash Flow for Q1 2026 stood at $4.2 million, down from $17.2 million in the prior quarter.
• Over the last five years, Net Cash Flow for EVMN reached as high as $17.2 million in Q4 2025 and fell as low as -$10.6 million in Q1 2025.
• Historically, Net Cash Flow has averaged $2.3 million across 3 years, with a median of $1.2 million in 2024.
• Across the five-year window, Net Cash Flow soared 1012.11% in 2025 and soared 140.27% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$1.9 million in 2024, then surged by 1012.11% to $17.2 million in 2025, then slumped by 75.37% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $4.2 million in Q1 2026, $17.2 million in Q4 2025, and -$10.6 million in Q1 2025.